These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36060244)

  • 21. Otomycosis in Damascus, Syria: Etiology and clinical features.
    Ismail MT; Al-Kafri A; Ismail M
    Curr Med Mycol; 2017 Sep; 3(3):27-30. PubMed ID: 29707671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular identification and antifungal susceptibilities of black Aspergillus isolates from otomycosis cases in Hungary.
    Szigeti G; Kocsubé S; Dóczi I; Bereczki L; Vágvölgyi C; Varga J
    Mycopathologia; 2012 Aug; 174(2):143-7. PubMed ID: 22359155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study on the microbial diversity of ear canal secretions from patients with otomycosis.
    Chen Z; Zhao Z
    Front Surg; 2024; 11():1277799. PubMed ID: 38450054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UK standards for microbiology investigations of ear infection (SMI B1) are inadequate for the recovery of fungal pathogens and laboratory diagnosis of otomycosis: A real-life prospective evaluation.
    Rawson TM; Fatania N; Abdolrasouli A
    Mycoses; 2022 Apr; 65(4):490-495. PubMed ID: 35080057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Fungal otitis externa in children: principles of diagnosis and rational therapy].
    Kryukov AI; Kunelskaya NL; Kunelskaya VY; Ivoylov AY; Shadrin GB; Machulin AI
    Vestn Otorinolaringol; 2020; 85(1):60-63. PubMed ID: 32241991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Response to Treatment in Patients with Otomycosis.
    Kiakojori K; Bagherpour Jamnani N; Khafri S; Mahdavi Omran S
    Iran J Otorhinolaryngol; 2018 Jan; 30(96):41-47. PubMed ID: 29387663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular epidemiology of otomycosis in Isfahan revealed a large diversity in causative agents.
    Aboutalebian S; Mahmoudi S; Mirhendi H; Okhovat A; Abtahi H; Chabavizadeh J
    J Med Microbiol; 2019 Jun; 68(6):918-923. PubMed ID: 31063125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of a recurrent Aspergillus niger otomycosis with local application of voriconazole.
    Chappe M; Vrignaud S; de Gentile L; Legrand G; Lagarce F; Le Govic Y
    J Mycol Med; 2018 Jun; 28(2):396-398. PubMed ID: 29673769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant otomycosis and dermatomycoses: a clinical and microbiological study.
    Ozcan M; Ozcan KM; Karaarslan A; Karaarslan F
    Eur Arch Otorhinolaryngol; 2003 Jan; 260(1):24-7. PubMed ID: 12520352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and treatment of otomycosis in southern China.
    Li Y; He L
    Mycoses; 2019 Nov; 62(11):1064-1068. PubMed ID: 31368588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Otomycosis in iran: a review.
    Gharaghani M; Seifi Z; Zarei Mahmoudabadi A
    Mycopathologia; 2015 Jun; 179(5-6):415-24. PubMed ID: 25633436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etiologic Agents of Otomycosis in the North-Western Area of Iran.
    Kazemi A; Majidinia M; Jaafari A; Ayatollahi Mousavi SA; Zarei Mahmoudabadi A; Alikhah H
    Jundishapur J Microbiol; 2015 Sep; 8(9):e21776. PubMed ID: 26495108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Presumption diagnosis: otomycosis. A 451 patients study].
    Hueso Gutiérrez P; Jiménez Alvarez S; Gil-Carcedo Sañudo E; Gil-Carcedo García LM; Ramos Sánchez C; Vallejo Valdezate LA
    Acta Otorrinolaringol Esp; 2005 May; 56(5):181-6. PubMed ID: 15960119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Otomycosis in Adolescent Patients Referred to the Therapeutic Centers in Babol City, Iran.
    Kiakojuri K; Rajabnia R; Jalili B; Khafri S; Omran SM
    Jundishapur J Microbiol; 2015 May; 8(5):e17138. PubMed ID: 26060563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Otomycosis in Africa: Epidemiology, diagnosis and treatment.
    Sangaré I; Amona FM; Ouedraogo RW; Zida A; Ouedraogo MS
    J Mycol Med; 2021 Jun; 31(2):101115. PubMed ID: 33516991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Epidemiology of otomycoses at the University Hospital of Yopougon (Abidjan-Ivory Coast)].
    Adoubryn KD; N'Gattia VK; Kouadio-Yapo GC; Nigué L; Zika DK; Ouhon J
    J Mycol Med; 2014 Jun; 24(2):e9-15. PubMed ID: 24139621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology, causative agents, and risk factors affecting human otomycosis infections.
    Abdelazeem M; Gamea A; Mubarak H; Elzawawy N
    Turk J Med Sci; 2015; 45(4):820-6. PubMed ID: 26422852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of otomycosis in Khouzestan Province, south-west Iran.
    Saki N; Rafiei A; Nikakhlagh S; Amirrajab N; Saki S
    J Laryngol Otol; 2013 Jan; 127(1):25-7. PubMed ID: 23164073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Otomycosis in the north of Iran: common pathogens and resistance to antifungal agents.
    Nemati S; Hassanzadeh R; Khajeh Jahromi S; Delkhosh Nasrollah Abadi A
    Eur Arch Otorhinolaryngol; 2014 May; 271(5):953-7. PubMed ID: 23595615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamisil, a potent alternative antifungal drug for otomycosis.
    Zarei Mahmoudabadi A; Seifi Z; Gharaghani M
    Curr Med Mycol; 2015 Mar; 1(1):18-21. PubMed ID: 28680976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.